Saraswat Neerja, Sood Aradhana, Verma Rajesh, Kumar Dhramesh, Kumar Sushil
Department of Dermatology, Base Hospital, Delhi Cantt, Delhi, India.
Department of Dermatology, Base Hospital, Lucknow Cantt, Lucknow, Uttar Pradesh, India.
Indian J Dermatol. 2020 May-Jun;65(3):193-198. doi: 10.4103/ijd.IJD_37_19.
Nail toxicity is a relatively uncommon cutaneous adverse effect of chemotherapeutic agents. Rapidly dividing cells of the nail matrix are perturbed by the antimitotic activity of these agents. Although most of these changes are cosmetic and regress once the therapy is completed, a few of these adverse effects are challenging to manage and require temporary or permanent suspension of chemotherapeutic agents.
A total of 205 patients with various malignancies and under chemotherapy in oncology ward of the hospital over a period of 3 months were screened for nail involvement postchemotherapy. Relevant details, protocol of chemotherapeutic agents were assessed. Nail examination was carried out in daylight and the changes were analyzed.
A total of 124 (60.4%) patients had nail changes due to chemotherapeutic agents. The most common change was diffuse hyperpigmentation in 101 (81.4%) patients commonly due to a combination of cyclophosphamide and adriamycin in 43 (42.5%) patients. Longitudinal melanonychia was seen in 36 (29%), Beau's lines in 31 (25%), onychomadesis in 17 (13.7%), Mees' lines in 15 (12%), paronychia in 12 (9.6%), subungual hyperkeratosis in 10 (8%), and Muehrcke's lines in 4 (3.2%) patients. All the patients who developed Muehrcke's lines were on a combination of cyclophosphamide/doxorubicin/5 FU. Exudative onycholysis was observed in 2 (1.6%) patients; both these patients were on paclitaxel therapy. A total 2 (1.6%) patients who developed exudative onycholysis were advised discontinuation and another substitute chemotherapy was advised. Therapy for 2 (1.6%) patients who developed acute paronychia due to gefitinib was temporarily suspended. Unfortunately, most of the patients were on multiple chemotherapeutic agents hence, we could not pinpoint one drug as a cause. Therefore, a combination of agents was implicated in most cases.
Nail toxicities are common with chemotherapeutic agents, however less importance is given to nail involvement. Apart from being cosmetically significant, a few adverse effects may warrant modification of the chemotherapy.
甲毒性是化疗药物相对罕见的皮肤不良反应。这些药物的抗有丝分裂活性会干扰甲母质中快速分裂的细胞。虽然这些变化大多只是影响美观,且在治疗结束后会消退,但其中一些不良反应处理起来颇具挑战性,需要暂时或永久停用化疗药物。
在3个月的时间里,对医院肿瘤科病房中接受化疗的205例各种恶性肿瘤患者进行了化疗后甲受累情况的筛查。评估了相关细节及化疗药物方案。在自然光下进行甲检查并分析变化情况。
共有124例(60.4%)患者出现了化疗药物所致的甲改变。最常见的改变是弥漫性色素沉着,101例(81.4%)患者出现此情况,其中43例(42.5%)患者通常是由于环磷酰胺和阿霉素联合使用所致。36例(29%)患者出现纵向黑甲,31例(25%)出现博氏线,17例(13.7%)出现甲脱落,15例(12%)出现米氏线,12例(9.6%)出现甲沟炎,10例(8%)出现甲下过度角化,4例(3.2%)出现穆勒克线。所有出现穆勒克线的患者均接受环磷酰胺/阿霉素/5-氟尿嘧啶联合治疗。2例(1.6%)患者出现渗出性甲剥离;这2例患者均接受紫杉醇治疗。共有2例(1.6%)出现渗出性甲剥离的患者被建议停药,并建议换用其他化疗药物。2例因吉非替尼导致急性甲沟炎的患者的治疗被暂时中断。不幸的是,大多数患者使用了多种化疗药物,因此我们无法确定某一种药物为病因。所以,大多数情况下是多种药物联合作用所致。
化疗药物导致甲毒性很常见,但甲受累情况未得到足够重视。除了具有重要的美容意义外,一些不良反应可能需要调整化疗方案。